What VSOP does

VSOP — Vereniging Samenwerkende Ouder- en Patiëntenorganisaties, legally VSOP - Patiëntenkoepel voor zeldzame en genetische aandoeningen — is the Dutch national umbrella organization for rare and genetic disease patient groups, founded in 1979 and headquartered at Amersfoortseweg 10E, Huis ter Heide, Netherlands. It is a non-profit vereniging with ANBI (Public Benefit Organization) status and approximately 85 member patient and parent organizations, collectively representing an estimated one million Dutch citizens affected by rare conditions (6–8% of the population). Approximately 51–100 staff execute its portfolio of national advocacy, European policy representation, expert-center coordination, awareness programming, and patient-facing digital services.

Its core products are policy and information platforms rather than commercial software. DiagnoseWijzer (launched February 2018, technical development by Creapolis) is a parent-maintained digital dossier that maps a child's diagnostic journey; the ECZA-platform supports patient organization participation in Ministry of VWS expertisecentra recognition; thematic websites (zichtopzeldzaam.nl, syndromen.net, ziekteonbekend.nl, zeldzameaandoening.nl) provide disease and care-pathway information; the Huisartsenbrochures program delivers 90+ rare-disease brochures to Dutch GPs; and the Vroegsignalering e-learning modules, developed with Erfocentrum, NHG, NVK and AJN, train frontline clinicians in early detection of rare disease in children. Recurring programs include the Nationale Conferentie Zeldzame Aandoeningen (NCZA), Zeldzameziektendag (Rare Disease Day, 28 February) with Zeldzame Engel Awards, the AGENDA newsletter, and the second National Plan Zeldzame Aandoeningen initiative under ZonMw.

Revenue derives from three streams: institutional subsidy from the Dutch Ministry of VWS (described as modest and decreasing), mandated membership contributions (€2,000/year for organizations with institutional subsidy; €500/year for non-subsidized members), and donations/bequests (including VriendenLoterij and tax-advantaged periodic gifts). Go-to-market is community-led: patient organizations join through a formal application and board approval at the General Members' Meeting, and individual patients are reached as donors and through member organizations' own channels. VSOP's strategic positioning hinges on its incumbency as the sole Dutch national rare-disease umbrella, its seat in EURORDIS and the EMA COMP, and its structural role in coordinating the recognition of approximately 300 expertisecentra for rare diseases in the Netherlands.

Name

VSOP

Legal name

VSOP - Patiëntenkoepel voor zeldzame en genetische aandoeningen

Website

https://vsop.nl

Company type

Private

Founded year

1979

Operating status

Operating

Headcount range

51–100 employees

Short description

VSOP is the Dutch national umbrella organization for ~85 patient and parent groups focused on rare and genetic diseases, founded in 1979. It coordinates expert center recognition, runs the DiagnoseWijzer digital diagnostic tool and e-learnings for GPs, and advocates at Dutch and EU policy levels.

Ownership category

akta.pro rank

Headquarters

HQ city

Soest

HQ country

Netherlands

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Marketing or Sales, Technology or R&D, Others

Revenue model

1. Membership contributions: Patient organizations pay annual membership contributions to VSOP. Organizations with institutional subsidy pay €2,000 per year, while those without institutional subsidy pay €500 per year. These rates are set by the Ministry of VWS as a condition for VSOP's institutional subsidy.
2. Institutional subsidy from Ministry of VWS: VSOP receives government (VWS) institutional subsidy. The government subsidy is modest and decreasing over time, leading VSOP to depend additionally on member contributions and donations.
3. Donations and bequests: VSOP receives individual donations, periodic gifts (5-year commitments with tax benefits), lottery contributions (VriendenLoterij), and bequests. As an ANBI (Public Benefit Organization), VSOP is exempt from gift and inheritance tax and donations are tax-deductible.

Pricing tiers

Go-to-market motion1 record

Distribution channels1 record

Marketing channels6 records

Core offering

VSOP is the national patient umbrella organization in the Netherlands for approximately 85 patient and parent organizations focused on rare and genetic disorders. It delivers collective advocacy, policy representation at national (VWS, ZonMw) and European (EURORDIS, EMA, European Commission) levels, coordination of expertisecentra (ECZA) assessments, and develops digital information tools (DiagnoseWijzer), GP education (Huisartsenbrochures, Vroegsignalering e-learnings), and awareness programs (Zeldzameziektendag, NCZA conference).

Product overview

VSOP operates as a national patient coalition offering a portfolio of digital platforms, information resources, and collaborative projects for rare and genetic diseases. Core products include DiagnoseWijzer (digital diagnostic tool), the ECZA-platform (for expertise center assessments), and multiple thematic websites (Zichtopzeldzaam, Syndromen.net, Ziekteonbekend.nl). The organization provides educational offerings through e-learnings (Vroegsignalering), develops practical information for general practitioners through the Huisartsenbrochures program, and organizes awareness initiatives including the annual Zeldzameziektendag and Zeldzame Engel Awards. Additional programs include the Nationale Conferentie Zeldzame Aandoeningen (NCZA), the AGENda newsletter, and various regional and national projects addressing rare disease care, diagnostics, and patient support.

Differentiator

Problem solved

Functional benefit

Brands

• Zeldzameziektendag: Annual awareness day for rare diseases held on February 28th, including media activities and the Zeldzame Engel Awards.
• Zeldzame Engel Awards
• NCZA
• ECZA
• AGENDA
• DiagnoseWijzer
• Vroegsignalering

Products and services

• DiagnoseWijzer
• ECZA-platform
• Huisartsenbrochures
• Vroegsignalering E-learnings

Quantifiable outcome

• Over 7,000 rare diseases represented through approximately 85 member organizations
• +3 more outcomes

Named customers1 record

Segments3 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

14 partnerships are on record, tiered core, major and minor.

• EURORDIScoreStrategic or Co-development PartnerVSOP works together with EURORDIS at the European level. EURORDIS is the European umbrella organization for rare disease patient organizations. VSOP participates in EURORDIS projects and events and represents Dutch patients in European rare disease policy development.
• European Patient Forum (EPF)coreStrategic or Co-development PartnerVSOP works together with the European Patient Forum, a broad coalition of patient organizations working on cross-cutting health policy issues at the European level.
• European Commission / ERDERAcoreStrategic or Co-development PartnerVSOP is a member of the national mirror group of ERDERA (European Research Dedicated for Rare Diseases), the EU's research infrastructure for rare diseases. VSOP is also represented in the COMP at EMA (European Medicines Agency) and is a project partner in EU-funded projects.
• Patiëntenfederatie NederlandcoreStrategic or Co-development PartnerVSOP is a member of the Patiëntenfederatie Nederland, the Dutch patients' federation. This membership provides additional benefits to VSOP member patients, as membership fees of patient organizations can be reimbursed by health insurers if patients mention that their organization is affiliated with VSOP and VSOP is a member of the Patiëntenfederatie.
• Integraal Kankercentrum Nederland (IKNL)coreStrategic or Co-development PartnerVSOP collaborated with IKNL and NFK to produce the report 'Kankerzorg in beeld: zeldzame kanker' (Rare Cancer Care report), which was handed to the Ministry of VWS during the NCZA conference in 2018. The report outlined ten key recommendations for improving rare cancer care.
• Nederlandse Federatie voor Kankerbestrijding (NFK)coreStrategic or Co-development PartnerVSOP and NFK collaborated as patient representatives alongside IKNL to map the challenges of rare cancer care and formulate recommendations for a national plan for rare cancer.
• Nederlandse Federatie van Universitair Medische Centra (NFU)coreStrategic or Co-development PartnerVSOP co-organizes the annual Nationale Conferentie Zeldzame Aandoeningen (NCZA) with the NFU, bringing together healthcare providers, patients, researchers, government, and industry.
• ErfocentrumcoreStrategic or Co-development PartnerVSOP develops e-learnings for GPs, youth doctors, and pediatricians together with the Erfocentrum. VSOP originally founded the Erfocentrum in 2000. The Erfocentrum handles overall project coordination and editing while VSOP coordinates and develops the medical content in cooperation with medical advisors.
• Nederlands Huisartsen Genootschap (NHG)majorStrategic or Co-development PartnerNHG is a partner in the Vroegsignalering (Early Detection) project, collaborating with VSOP and the Erfocentrum on e-learnings for GPs on recognizing rare diseases in children. The e-learnings are available via the NHG website.
• Nederlandse Vereniging voor Kindergeneeskunde (NVK)majorStrategic or Co-development PartnerNVK is a partner in the Vroegsignalering project, providing clinical expertise for the development of e-learnings for pediatricians on rare disease detection. VSOP collaborates with NVK on developing care standards and guidelines.
• Jeugdartsen Nederland (AJN)majorStrategic or Co-development PartnerAJN is a partner in the Vroegsignalering project, collaborating with VSOP on e-learnings for youth doctors on recognizing rare diseases. E-learnings are accessible via the AJN website.
• Vereniging Klinische Genetica Nederland (VKGN)minorStrategic or Co-development PartnerVKGN provides advisory input on the development of e-learnings for healthcare professionals on rare disease detection, contributing clinical genetics expertise.
• ZonMwcoreStrategic or Co-development PartnerZonMw is the Dutch health research funding organization that will oversee the development of the new National Plan Zeldzame Aandoeningen, as announced by the Minister of VWS in 2025. VSOP is involved as a key stakeholder in this process.
• TNO and NSPOHminorStrategic or Co-development PartnerTNO (Nederlandse Organisatie voor toegepast wetenschappelijk onderzoek) and NSPOH (Netherlands School of Public Health & Occupational Medicine) provide advisory input on the development of e-learnings for healthcare professionals on rare disease detection.

Scale indicators6 records

Recent moves6 records

Expansion highlights6 records

Others

• Integraal Kankercentrum Nederland (IKNL): Dutch integral cancer center and VSOP partner on rare cancer policy reports and conferences. Comparable role in coordinating expertise and producing policy-grade research for a defined patient population.
• Nederlandse Federatie van Universitair Medische Centra (NFU): Association of Dutch UMCs and co-organizer with VSOP of the annual Nationale Conferentie Zeldzame Aandoeningen. Operates in the same expertisecentra ecosystem but as a provider-side rather than patient-side organization.
• ZonMw: Dutch health research and innovation funder that will oversee the development of the new National Plan Zeldzame Aandoeningen starting in 2026. Direct policy counterpart and funding-flow partner for VSOP.
• Nederlandse Federatie voor Kankerbestrijding (NFK): Dutch federation of cancer patient organizations and direct collaborator with VSOP on rare cancer care. Adjacent patient-umbrella operating in a specific disease vertical with overlapping advocacy methodologies.
• Erfocentrum: Dutch center for hereditary and congenital conditions, originally founded by VSOP in 2000. Direct institutional relationship — VSOP develops medical content for Erfocentrum-led projects including the Vroegsignalering e-learnings.

Direct peers

• EURORDIS - Rare Diseases Europe: European umbrella organization for rare disease patient organizations. Most directly comparable peer — VSOP is itself a member of EURORDIS and they jointly shape EU rare disease policy (COMP at EMA, ERDERA mirror group).
• Orphanet: International reference portal for rare diseases and orphan drugs, offering expertisecentra directories, disease classifications, and patient resources. Comparable information-infrastructure function overlapping with VSOP's Zichtopzeldzaam and Syndromen.net sites.
• Patiëntenfederatie Nederland: Dutch national patient federation that aggregates patient organizations across all disease areas. VSOP is a member; structurally analogous umbrella model in the same Dutch healthcare policy environment, but with broader scope beyond rare diseases.

Regional players

• Genetic Alliance: U.S.-based umbrella advocating for individuals with genetic conditions through member organizations and policy engagement. Closely mirrors VSOP's dual rare-and-genetic disease mandate and coalition-driven advocacy model.
• NORD - National Organization for Rare Disorders: U.S. national umbrella for rare disease patient organizations with an analogous advocacy, policy, and member-coordination role. Functions as the US counterpart to VSOP, providing a strong model and benchmark but operating in a different geography.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat5 records

Key risks4 records

Key highlights7 records

Customer concentration

• Xx.com/vsopzeldzaam

Revenue estimate

Valuation estimate

Number of profiles

Profiles2 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about VSOP